blog

Machavert Pharmaceuticals RAL GTPase Inhibitors Suppress KRAS Cancer Metastasis in Preclinical Animal Model

web-admin / March 16, 2025

– Machavert hits its preclinical proof of principle milestone that small molecule RAL GTPase inhibitors suppress KRAS mutant cancer metastasis […]

blog

CEOCFO Magazine interview with Machavert Pharmaceuticals CEO about taking down the KRAS cancer

web-admin / March 16, 2025

AURORA, Colo., Feb. 17, 2020 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, was featured in

blog

Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers

web-admin / March 16, 2025

Aurora, Colo, August 27, 2019 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, announced today that